- Home
- IMCR vs ZLAB Comparison
IMCR vs ZLAB Comparison
Compare IMCR & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- ZLAB
- Stock Information
- Founded
- IMCR 2008
- ZLAB 2013
- Country
- IMCR United Kingdom
- ZLAB China
- Employees
- IMCR N/A
- ZLAB N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- ZLAB Health Care
- Exchange
- IMCR Nasdaq
- ZLAB Nasdaq
- Market Cap
- IMCR 1.7B
- ZLAB 1.8B
- IPO Year
- IMCR 2021
- ZLAB 2017
- Fundamental
- Price
- IMCR $32.93
- ZLAB $31.24
- Analyst Decision
- IMCR Buy
- ZLAB Strong Buy
- Analyst Count
- IMCR 14
- ZLAB 4
- Target Price
- IMCR $74.75
- ZLAB $52.50
- AVG Volume (30 Days)
- IMCR 267.8K
- ZLAB 976.3K
- Earning Date
- IMCR 11-05-2024
- ZLAB 11-12-2024
- Dividend Yield
- IMCR N/A
- ZLAB N/A
- EPS Growth
- IMCR N/A
- ZLAB N/A
- EPS
- IMCR N/A
- ZLAB N/A
- Revenue
- IMCR $280,914,000.00
- ZLAB $322,711,000.00
- Revenue This Year
- IMCR $25.60
- ZLAB $48.34
- Revenue Next Year
- IMCR $10.63
- ZLAB $47.12
- P/E Ratio
- IMCR N/A
- ZLAB N/A
- Revenue Growth
- IMCR 27.95
- ZLAB 28.16
- 52 Week Low
- IMCR $29.72
- ZLAB $13.48
- 52 Week High
- IMCR $76.98
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- IMCR 52.76
- ZLAB 70.41
- Support Level
- IMCR $31.10
- ZLAB $31.52
- Resistance Level
- IMCR $35.47
- ZLAB $36.60
- Average True Range (ATR)
- IMCR 1.49
- ZLAB 1.36
- MACD
- IMCR 0.17
- ZLAB 0.34
- Stochastic Oscillator
- IMCR 51.98
- ZLAB 58.60
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.